Donna Sutherland
Celgene
6 Papers
5 Citations
Donna Sutherland is an academic researcher from Celgene. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers
Jos van der Velden,Ying Ye,James D. Nolin,Sidra M. Hoffman,David G. Chapman,Karolyn G. Lahue,Sarah Abdalla,Peng Chen,Yong Liu,Brydon L. Bennett,Nasreen Khalil,Donna Sutherland,William T. Smith,Gerald Horan,Mahmoud Assaf,Zebulun Horowitz,Rajesh Chopra,R. Stevens,Maria Palmisano,Yvonne M. W. Janssen-Heininger,Peter H. Schafer +20 more
TL;DR: Results illustrate JNK enzymatic activity involvement during pulmonary fibrosis, and support systemic biomarker use for tracking disease progression and the potential clinical benefit of this novel intervention in IPF.
Patent
Biomarkers for the treatment of psoriasis
Peter H. Schafer,Yong Lin,Donna Sutherland +2 more
- 15 Jun 2011
TL;DR: In this article, the biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis were provided, which can be used to monitor progress of treatment effectiveness and patient compliance in patients who are receiving treatment.
5
Patent
Biomarkers for treatment of psoriasis
Peter H. Schafer,Yong Lin,Donna Sutherland +2 more
- 27 Oct 2016
TL;DR: In this paper, a method of predicting whether a patient is responsive to a treatment for psoriasis comprises: obtaining cells from the patient; culturing the cells in the presence or absence of a treatment compound; measuring the level of a cell marker selected from CD11c, CD3, CD56, ICAM-1, Foxp3, HLA-DR and combinations thereof; where a decreased level of the cell marker indicates the likelihood of an effective patient response to the treatment compound.
Soutenir l’équité en santé pour les Premières Nations, les Inuits et les Métis
TL;DR: The Centre de collaboration nationale de la santé autochtone (CCNSA) as mentioned in this paper is unique parmi les centres of collaboration nationales, car il is le seul centre axé sur la santsé d'une population, et leur contribution to la réaction de la Santé publique du Canada à la pandémie de maladie à coronavirus 2019 (COVID-19).
Patent
Biomarqueurs pour le traitement du psoriasis
Peter H. Schafer,Yong Lin,Donna Sutherland +2 more
- 15 Jun 2011
TL;DR: L'expression of ces genes ou de ces marqueurs cellulaires peut etre utilisee pour surveiller l'evolution de l'efficacite du traitement and of theobservance du patient chez des patients atteints de psoriasis qui recoivent un traitement.